This post is not an endorsement of suramin.
I looked up material, because I'd never heard of suramin.
"Suramin is a 100-year-old drug developed to treat African sleeping sickness and river blindness. Though it has been investigated for other diseases, including cancer, it is not approved for any therapeutic use in the United States.
However, a small, randomized clinical trial conducted by
Robert Naviaux, MD, PhD , professor of medicine, pediatrics and pathology, and colleagues at University of California San Diego School of Medicine have found that a single intravenous dose of suramin produced dramatic, but
transient, improvement of core symptoms of
autism spectrum disorder (ASD). Currently, there are no drugs approved for treating the core symptoms of ASD.
More broadly, the trial findings support the “cell danger response theory,” which posits that autism and other chronic conditions are fundamentally driven by metabolic dysfunction—and thus treatable. Naviaux and his co-authors propose larger, longer clinical trials to assess suramin (or similar drugs) as an ASD treatment.
Special note from the researchers: Suramin is not approved for the treatment of autism. Like many intravenous drugs, when administered improperly by untrained personnel, at the wrong dose and schedule, without careful measurement of drug levels and monitoring for toxicity, suramin can cause harm. Careful clinical trials will be needed over several years at several sites to learn how to use low-dose suramin safely in autism, and to identify drug-drug interactions and rare side effects that cannot currently be predicted. We strongly caution against the unauthorized use of suramin.
Suramin and Autism - UC San Diego Health
https://www.rxlist.com/consumer_suramin/drugs-condition.htm
"Suramin remains controversial. Is its polypharmacology a liability or an asset? Is it toxic or protective? Dated or timeless? Whatever the verdict on suramin, there is hardly another molecule with as many biological activities. The list of potential targets is indeed impressive, and the publication stream on suramin is not stagnating. The large majority of papers are not about trypanosomes or trypanosomiasis. The list of potential targets has to be taken with a grain of salt, though, since the negative charges of suramin, and its promiscuity in protein binding, can cause all kinds of artifacts."
https://journals.asm.org/doi/10.1128/AAC.01168-19